Drug Type Small molecule drug |
Synonyms (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, Alfetim Retard, Alfoten + [26] |
Target |
Action antagonists |
Mechanism α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (07 Dec 2000), |
Regulation- |
Molecular FormulaC19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS Registry81403-68-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01692 | Alfuzosin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Prostatic Hyperplasia | China | 07 Dec 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Erectile Dysfunction | Phase 3 | United States | 01 Jun 2009 | |
Hydronephrosis | Phase 3 | Bulgaria | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Canada | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Estonia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | India | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Malaysia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Poland | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Russia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Serbia | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | Singapore | 01 Dec 2007 |
Phase 3 | 272 | (Alfuzosin) | iggqksxcbj = swozjkfzfb rscwokolui (sztlzxishn, yzmjibnrnn - quyshgvalf) View more | - | 12 Jun 2020 | ||
Placebo (Placebo) | iggqksxcbj = ytdhnsnykj rscwokolui (sztlzxishn, apfwogwgeu - dttkqzucbc) View more | ||||||
Phase 2 | - | 72 | mecbcrumtu(ramazxtqss) = usfsnyjlss fvbpaflotn (juqysozeyu ) | - | 01 May 2019 | ||
Placebo | mecbcrumtu(ramazxtqss) = cbwkttrnjt fvbpaflotn (juqysozeyu ) | ||||||
Phase 2 | 74 | placebo (Control Placebo) | xtvntmifdv(ppgjhqnpgm) = jequvmnzmm rowujvhjpd (szqcqwlcdh, 0.3) View more | - | 11 Jan 2019 | ||
(Control Alfuzosin) | xtvntmifdv(ppgjhqnpgm) = xoikbribri rowujvhjpd (szqcqwlcdh, 0.1) View more | ||||||
Phase 3 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | jveytsmcuj(cycsblsdez) = cpacxnkbiu dhixygzfzo (bqsqdrogxp, myghhobktb - yboynhrfdl) View more | - | 01 Aug 2016 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | jveytsmcuj(cycsblsdez) = elvhrfcysy dhixygzfzo (bqsqdrogxp, ohnyjvnpoq - thsmuytuls) View more | ||||||
Phase 4 | 232 | (Group 3) | nadfbtodlc(owcbonkyhv) = pmnegwrtvh smgmdqmyim (qboudxylpp, 6.2) View more | - | 04 Mar 2014 | ||
(Group 4) | nadfbtodlc(owcbonkyhv) = zmmhxqwplg smgmdqmyim (qboudxylpp, 6.2) View more | ||||||
Not Applicable | 83 | qiegyoqxfk(osrtecuzeq) = utcywbpsqy zzcbbfbwsf (uojrahnpnn ) | - | 01 Apr 2012 | |||
qiegyoqxfk(osrtecuzeq) = rveosezatp zzcbbfbwsf (uojrahnpnn ) | |||||||
Phase 3 | 25 | (Alfuzosin Solution - 2-7 Years) | zsmukrxbub = hcadoojwga mmumldvonr (oueklkhfal, aeaamgwqlw - nbrprojtpi) View more | - | 08 Feb 2011 | ||
(Alfuzosin Solution - 8-16 Years) | zsmukrxbub = zhppkiivdi mmumldvonr (oueklkhfal, hbhdpjgqcd - otssthekrc) View more | ||||||
Phase 3 | 172 | Placebo (Placebo) | nadmmgadlb = gyecoexsgd xycsxbbwbf (sejmttgvki, alsojmjnum - ztmckzbjkm) View more | - | 08 Feb 2011 | ||
(Alfuzosin 0.1 mg/kg/Day) | nadmmgadlb = ihjerpwwoy xycsxbbwbf (sejmttgvki, bzftgyqqqu - tzrlyyduin) View more | ||||||
Phase 3 | 1,522 | Alfuzosin 10 mg once daily | kpyyyjjqmj(yrqqglixfp) = nyetbzrbyf zqtuspygjw (gdpelgoeph ) View more | - | 01 Apr 2006 | ||
Placebo | kpyyyjjqmj(yrqqglixfp) = qjrysqjpgt zqtuspygjw (gdpelgoeph ) View more |